BioWorld

April 23, 2008

Resolvyx Adds $25M to Move First Resolvin Drugs into Clinic

Gearing up to move its first two drug candidates into the clinic this year, Resolvyx Pharmaceuticals Inc. padded its bank account with a $25 million Series B round from new and existing investors. (BioWorld Today) Read More

Congress Told Foreign Plants are 'Ticking Time Bombs'

'Pseudokinase' Found Active, Without Binding Magnesium

CuraGen Sells Cancer Drug to TopoTarget for $45M

Genzyme Must File 2 BLAs for Myozyme Formulations

Theravance Cuts Staff 40%; Telavancin Inches Along

FDA Approves Cimzia for Crohn's Disease

Spectrum Shares Falls on Ozarelix Miss

ImClone, BioVex Secure SPAs For Late-Stage Cancer Studies

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...